Richard Vivero, MD
Otolaryngology · Miami, FLNPI 1669620589
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 100.0% of the total across 88 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 20 manufacturers, the largest accounting for just 18.0% — the pattern of someone who eats at a lot of different presentations. 2025 is the largest year on record at $1,149, 3.9 times the $296 reported in 2019.
Across 88 payments — averaging $44.35 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Aerin Medical Inc.$703
- Medtronic$579
- Sanofi$536
- Regeneron Healthcare Solutions, Inc.$366
- Optinose US, Inc.$320
- Pentax Of America, Inc.$306
- plus $1K from 14 others
What the payments were for
- Food & beverage$3,902100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Aerin Medical Inc. | 9 | $703 |
| Medtronic | 4 | $579 |
| Sanofi | 15 | $536 |
| Regeneron Healthcare Solutions, Inc. | 10 | $366 |
| Optinose US, Inc. | 12 | $320 |
| Pentax Of America, Inc. | 5 | $306 |
| GSK | 10 | $253 |
| Intersect ENT, Inc. | 2 | $180 |
| Inspire Medical Systems, Inc. | 1 | $161 |
| Acclarent, Inc | 2 | $138 |
| Alk-abello, Inc | 4 | $70 |
| Integra Lifesciences Corporation | 2 | $57 |
| AbbVie | 3 | $55 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $44 |
| Hikma Pharmaceuticals USA | 2 | $32 |
| Smith+Nephew | 1 | $26 |
| Agiliti Surgical, Inc. | 2 | $25 |
| Mckesson Medical-surgical, Inc. | 1 | $20 |
| Aroa Biosurgery Incorporated | 1 | $16 |
| Lilly USA, LLC | 1 | $15 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- VIVAER STYLUS$434
- RHINAER STYLUS$434
- PROPEL$269
- PENTAX Medical$216
- STEALTHSTATION S8 PLATFORM$195
- Inspire$161
- SINUVA$150
- DUPIXENT$124
- Xhance$111
- INSPIRA$108
- C2 CryoBalloon Focal Controller$108
- C2 Cryoballoon$108
- TruDi Nav Cable$106
How this compares
$3,902 in reported general payments places this provider in the 70th percentile of 586 otolaryngology providers in Florida.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Dupixent SyringeDupilumab | 13 | $56,272 |
| XhanceFluticasone Propionate | 11 | $6,938 |
| Fluticasone Propionate | 303 | $5,379 |
| Ipratropium Bromide | 177 | $4,579 |
| Azelastine Hcl | 168 | $4,411 |
| Clotrimazole-BetamethasoneClotrimazole/Betamethasone Dip | 56 | $3,820 |
| Azelastine-FluticasoneAzelastine/Fluticasone | 16 | $2,340 |
| Fluocinolone Acetonide Oil | 30 | $1,392 |
| Famotidine | 80 | $1,050 |
| Amoxicillin-Clavulanate PotassAmoxicillin/Potassium Clav | 54 | $572 |
| Ofloxacin | 25 | $492 |
| Nystatin | 14 | $418 |
| Omeprazole | 28 | $389 |
| Methylprednisolone | 39 | $311 |
| Doxycycline Hyclate | 21 | $188 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Optinose US, Inc.Xhance | $320 | $6,93811 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 586 otolaryngology providers in Florida.
Other otolaryngology in Miami
- Maria SuurnaMiami$189K
- Agustin ArrietaMiami$95K
- Francisco PernasMiami$70K
- Adrien EshraghiMiami$41K
- Michael HofferMiami$24K
- Corinna LevineMiami$16K
- Jason LeibowitzMiami$13K
- Donald WeedMiami$8K
- Cecelia DamaskOrlando$707K
- Ralph TufanoSarasota$469K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.